This robust patient-level meta-analysis includes 1,350 HFrEF patients from CHAMPION, GUIDE-HF, and LAPTOP-HF studies to assess the impact on hemodynamic monitoring on heart failure hospitalizations over 12 months and survival over the full follow-up across trials.
Presented at the THT 2023 conference, the combined patient population confirmed previous findings of decreased heart failure hospitalizations and improved survival with the use of hemodynamic monitoring devices like the CardioMEMS™ HF System.
HFrEF patients over 2 years of follow-up demonstrated that remote hemodynamic monitoring improves all-cause mortality and reduces heart failure hospitalizations.
25% reduction in mortality at 2 years1
36% decrease in HFHs at 12 months1
This patient-level meta-analysis includes HFrEF (baseline EF ≤ 40%) patients from three separate studies:
This patient-level meta-analysis of HFrEF patients over 2 years of follow-up demonstrates that remote hemodynamic monitoring improves all-cause mortality and reduces heart failure hospitalizations.
GUIDE-HF: Lindenfeld J, Zile MR, Desai AS, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomized controlled trial. Lancet. 2021;398:991-1001.
CHAMPION: Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, Strickland W, Neelagaru S, Raval N, Krueger S, Weiner S, Shavelle D, Jeffries B, Yadav JS; CHAMPION Trial Study Group. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377:658–666. doi: 10.1016/S0140-6736(11)60101-3.
LAPTOP-HF: Abraham; Adamson; Costanzo; Eigler; Gold; Klapholz; Maurer; Saxon; Singh; Troughton. Hemodynamic Monitoring in Advanced Heart Failure: Results from the LAPTOP-HF Trial. Journal of Cardiac Failure Vol. 22 No. 11 November 2016
Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.
CardioMEMS HF System Indications and Usage: The CardioMEMS HF System is indicated for wirelessly measuring and monitoring pulmonary artery pressure and heart rate in NYHA Class II or III heart failure patients who either have been hospitalized for heart failure in the previous year and/or have elevated natriuretic peptides. The hemodynamic data are used by physicians for heart failure management with the goal of controlling pulmonary artery pressures and reducing heart failure hospitalizations.
CardioMEMS HF System Contraindications: The CardioMEMS HF System is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one month post implant.
CardioMEMS HF System Potential Adverse Events: Potential adverse events associated with the implantation procedure include, but are not limited to, the following: air embolism, allergic reaction, infection, delayed wound healing, arrhythmias, bleeding, hemoptysis, hematoma, nausea, cerebrovascular accident, thrombus, cardiovascular injury, myocardial infarction, death, embolization, thermal burn, cardiac perforation, pneumothorax, thoracic duct injury and hemothorax.